Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Feb;156(2):467-474.
doi: 10.1016/j.ygyno.2019.10.009. Epub 2019 Dec 16.

GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients

Jay W Carlson  1 , James Kauderer  2 , Alan Hutson  3 , Jeanne Carter  4 , Jane Armer  5 , Suzy Lockwood  6 , Susan Nolte  7 , Bob R Stewart  8 , Lari Wenzel  9 , Joan Walker  10 , Aimee Fleury  11 , Albert Bonebrake  12 , John Soper  13 , Cara Mathews  14 , Oliver Zivanovic  15 , Wm Edward Richards  16 , Annie Tan  17 , David S Alberts  18 , Richard R Barakat  19
Affiliations
Multicenter Study

GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients

Jay W Carlson et al. Gynecol Oncol. 2020 Feb.

Abstract

Objectives: To evaluate the incidence and risk factors for lymphedema associated with surgery for gynecologic malignancies on GOG study 244.

Methods: Women undergoing a lymph node dissection for endometrial, cervical, or vulvar cancer were eligible for enrollment. Leg volume was calculated from measurements at 10-cm intervals starting 10 cm above the bottom of the heel to the inguinal crease. Measurements were obtained preoperatively and postoperatively at 4-6 weeks, and at 3-, 6-, 9-, 12-, 18-, and 24- months. Lymphedema was defined as a limb volume change (LVC) ≥10% from baseline and categorized as mild: 10-19% LVC; moderate: 20-40% LVC; or severe: >40% LVC. Risk factors associated with lymphedema were also analyzed.

Results: Of 1054 women enrolled on study, 140 were inevaluable due to inadequate measurements or eligibility criteria. This left 734 endometrial, 138 cervical, and 42 vulvar patients evaluable for LVC assessment. Median age was 61 years (range, 28-91) in the endometrial, 44 years (range, 25-83) in the cervical, and 58 years (range, 35-88) in the vulvar group. The incidence of LVC ≥10% was 34% (n = 247), 35% (n = 48), and 43% (n = 18), respectively. The peak incidence of lymphedema was at the 4-6 week assessment. Logistic regression analysis showed a decreased risk with advanced age (p = 0.0467). An exploratory analysis in the endometrial cohort showed an increased risk with a node count >8 (p = 0.033).

Conclusions: For a gynecologic cancer, LVC decreased with age greater than 65, but increased with a lymph node count greater than 8 in the endometrial cohort. There was no association with radiation or other risk factors.

Keywords: Cervical cancer; Endometrial cancer; Lymphadenectomy; Lymphedema; Staging; Vulvar cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. Alan Hutson received grant funding from NRG SDMC. Dr. Jeanne Carter received grant funding from grant RO1 as a co-investigator. Dr. Jane Armer received grant funding from NCI LEG study. Dr. Suzy Lockwood received grant funding from NIH ROICA 162139. Dr. Susan Nolte grant funding from NCI ROICA162139, salary support to institution, payments for patient accrual from GOG and NRG Oncology to institution. Dr. Robert Stewart received grant funding from NCI LEG study. Dr. Lari Wenzel received grant funding from NRG Oncology. All other co-authors have no conflicts of interest to declare.

Figures

Figure 1.
Figure 1.. Flow Chart of Enrolled Patients.
To be eligible for risk factor analysis, patients were required to have a baseline measurement and at least four follow-up measurements.
See this image and copyright information in PMC

References

    1. Koh WJ, Abu-Rustum NR, Bean S, Bradely K, Campos SM, Cho KR, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:64–84. - PubMed
    1. Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:170–99. - PubMed
    1. Koh WJ, Greer BE, Abu-Rustum NR, Campos SM, Cho KR, Chon HS, et al. Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:92–120. - PubMed
    1. Halaska MJ, Novackova M, Mala I, Pluta M, Chmel R, Stankusova H, et al. A prospective study of postoperative lymphedema after surgery for cervical cancer. Int J Gynecol Cancer. 2010;20:900–4. - PubMed
    1. Kim JH, Choi JH, Ki EY, Lee SJ, Yoon JH, Lee KH, et al. Incidence and risk factors of lower-extremity lymphedema after radical surgery with or without adjuvant radiotherapy in patients with FIGO stage I to stage IIA cervical cancer. Int J Gynecol Cancer. 2012;22:686–91. - PubMed

Publication types